Literature DB >> 27529376

Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.

Cathryn L Ugalde1,2,3,4, David I Finkelstein2, Victoria A Lawson3, Andrew F Hill5,6.   

Abstract

Proteinopathies represent a group of diseases characterized by the unregulated misfolding and aggregation of proteins. Accumulation of misfolded protein in the central nervous system (CNS) is associated with neurodegenerative diseases, such as the transmissible spongiform encephalopathies (or prion diseases), Alzheimer's disease, and the synucleinopathies (the most common of which is Parkinson's disease). Of these, the pathogenic mechanisms of prion diseases are particularly striking where the transmissible, causative agent of disease is the prion, or proteinaceous infectious particle. Prions are composed almost exclusively of PrPSc ; a misfolded isoform of the normal cellular protein, PrPC , which is found accumulated in the CNS in disease. Today, mounting evidence suggests other aggregating proteins, such as amyloid-β (Aβ) and α-synuclein (α-syn), proteins associated with Alzheimer's disease and synucleinopathies, respectively, share similar biophysical and biochemical properties with PrPSc that influences how they misfold, aggregate, and propagate in disease. In this regard, the definition of a 'prion' may ultimately expand to include other pathogenic proteins. Unifying knowledge of folded proteins may also reveal common mechanisms associated with other features of disease that are less understood, such as neurotoxicity. This review discusses the common features Aβ and α-syn share with PrP and neurotoxic mechanisms associated with these misfolded proteins. Several proteins are known to misfold and accumulate in the central nervous system causing a range of neurodegenerative diseases, such as Alzheimer's, Parkinson's, and the prion diseases. Prions are transmissible misfolded conformers of the prion protein, PrP, which seed further generation of infectious proteins. Similar effects have recently been observed in proteins associated with Alzheimer's disease and the synucleinopathies, leading to the proposition that the definition of a 'prion' may ultimately expand to include other pathogenic proteins. Unifying knowledge of misfolded proteins may also reveal common mechanisms associated with other features of disease that are less understood, such as neurotoxicity.
© 2016 International Society for Neurochemistry.

Entities:  

Keywords:  Alzheimer's disease; amyloid-β; neurodegenerative diseases; prion; prion disease; synucleinopathies

Mesh:

Substances:

Year:  2016        PMID: 27529376     DOI: 10.1111/jnc.13772

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  28 in total

Review 1.  The role of lipids in α-synuclein misfolding and neurotoxicity.

Authors:  Cathryn L Ugalde; Victoria A Lawson; David I Finkelstein; Andrew F Hill
Journal:  J Biol Chem       Date:  2019-05-07       Impact factor: 5.157

2.  α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects.

Authors:  Simona Daniele; Deborah Pietrobono; Jonathan Fusi; Caterina Iofrida; Lucia Chico; Lucia Petrozzi; Annalisa Lo Gerfo; Filippo Baldacci; Fabio Galetta; Gabriele Siciliano; Ubaldo Bonuccelli; Gino Santoro; Maria Letizia Trincavelli; Ferdinando Franzoni; Claudia Martini
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

Review 3.  Pathways to neurodegeneration: lessons learnt from unbiased genetic screens in Drosophila.

Authors:  Neha Singhal; Manish Jaiswal
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

4.  Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer's disease-type beta-amyloid neuropathological mechanisms.

Authors:  Lap Ho; Kenjiro Ono; Mayumi Tsuji; Paolo Mazzola; Risham Singh; Giulio M Pasinetti
Journal:  Expert Rev Neurother       Date:  2017-11-14       Impact factor: 4.618

5.  Hereditary spastic paraplegia: gain-of-function mechanisms revealed by new transgenic mouse.

Authors:  Liang Qiang; Emanuela Piermarini; Hemalatha Muralidharan; Wenqian Yu; Lanfranco Leo; Laura E Hennessy; Silvia Fernandes; Theresa Connors; Philip L Yates; Michelle Swift; Lyandysha V Zholudeva; Michael A Lane; Gerardo Morfini; Guillermo M Alexander; Terry D Heiman-Patterson; Peter W Baas
Journal:  Hum Mol Genet       Date:  2019-04-01       Impact factor: 6.150

Review 6.  The multiple functions of PrPC in physiological, cancer, and neurodegenerative contexts.

Authors:  Izabella Grimaldi; Felipe Saceanu Leser; José Marcos Janeiro; Bárbara Gomes da Rosa; Ana Clara Campanelli; Luciana Romão; Flavia Regina Souza Lima
Journal:  J Mol Med (Berl)       Date:  2022-09-03       Impact factor: 5.606

7.  Dihydroceramide Desaturase 1 Inhibitors Reduce Amyloid-β Levels in Primary Neurons from an Alzheimer's Disease Transgenic Model.

Authors:  Lara Ordóñez-Gutiérrez; Irene Benito-Cuesta; José Luis Abad; Josefina Casas; Gemma Fábrias; Francisco Wandosell
Journal:  Pharm Res       Date:  2018-02-06       Impact factor: 4.200

8.  Studies on the Neuromodulatory Effects of Ginkgo biloba on Alterations in Lipid Composition and Membrane Integrity of Rat Brain Following Aluminium Neurotoxicity.

Authors:  Sonia Verma; Pavitra Ranawat; Bimla Nehru
Journal:  Neurochem Res       Date:  2020-06-27       Impact factor: 4.414

Review 9.  Emerging roles of extracellular vesicles in neurodegenerative disorders: focus on HIV-associated neurological complications.

Authors:  Guoku Hu; Lu Yang; Yu Cai; Fang Niu; Frank Mezzacappa; Shannon Callen; Howard S Fox; Shilpa Buch
Journal:  Cell Death Dis       Date:  2016-11-24       Impact factor: 8.469

Review 10.  Metal Dyshomeostasis and Their Pathological Role in Prion and Prion-Like Diseases: The Basis for a Nutritional Approach.

Authors:  Mattia Toni; Maria L Massimino; Agnese De Mario; Elisa Angiulli; Enzo Spisni
Journal:  Front Neurosci       Date:  2017-01-19       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.